Resveratrol used as nanotherapeutic: a promising additional therapeutic tool against hormone-sensitive, hormone-insensitive and resistant prostate cancer.

IF 1.5 Q3 UROLOGY & NEPHROLOGY American journal of clinical and experimental urology Pub Date : 2023-01-01
Jasmin Katrin Badawi
{"title":"Resveratrol used as nanotherapeutic: a promising additional therapeutic tool against hormone-sensitive, hormone-insensitive and resistant prostate cancer.","authors":"Jasmin Katrin Badawi","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Prostate cancer is one of the most common cancers in men. Despite the development of diverse therapeutic agents for different types and stages, the progression or spread of the disease is inevitable. Another problem is the development of resistance of cancer cells to available therapeutics. Therefore, additional medicaments are urgently needed. Resveratrol is a polyphenolic phytoalexin found in numerous plants and fruits like red grapes or blueberries. Resveratrol possesses antiproliferative, anti-angiogenic and anticancer activities well proven in different types of cancer including prostate cancer. To date, it is not used clinically due to poor solubility, low bioavailability, and other limiting factors. In order to overcome these limitations, novel nanoparticle-based formulations were developed over the past years. In this review article, studies about the effect of resveratrol on prostate cancer cells are discussed focusing especially on those studies using nanotechnology. An electronic literature research was performed utilizing PubMed in August 2022. Scientific publications, which examine resveratrol using nanotechnology, are discussed. The studies clearly indicate that resveratrol-loaded nanoparticles exhibited a remarkable anti-cancer activity in various hormone-sensitive and hormone-insensitive prostate cancer cell lines including docetaxel-resistant prostate-cancer cells. The types of nanoparticles that were used varied and influenced the outcome. Additionally, the meaning of the surface functionality of the nanoparticles is emphasized. No reduction of the anti-proliferative activity of resveratrol was shown when used encapsulated. Additionally, synergistic effects of resveratrol and docetaxel were proven. Resveratrol-loaded nanoparticles, especially when combined, may represent the next generation of anticancer substances. However, further in vivo/clinical studies are necessary to confirm their clinical effectiveness.</p>","PeriodicalId":7438,"journal":{"name":"American journal of clinical and experimental urology","volume":"11 1","pages":"1-11"},"PeriodicalIF":1.5000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10009313/pdf/ajceu0011-0001.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical and experimental urology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Prostate cancer is one of the most common cancers in men. Despite the development of diverse therapeutic agents for different types and stages, the progression or spread of the disease is inevitable. Another problem is the development of resistance of cancer cells to available therapeutics. Therefore, additional medicaments are urgently needed. Resveratrol is a polyphenolic phytoalexin found in numerous plants and fruits like red grapes or blueberries. Resveratrol possesses antiproliferative, anti-angiogenic and anticancer activities well proven in different types of cancer including prostate cancer. To date, it is not used clinically due to poor solubility, low bioavailability, and other limiting factors. In order to overcome these limitations, novel nanoparticle-based formulations were developed over the past years. In this review article, studies about the effect of resveratrol on prostate cancer cells are discussed focusing especially on those studies using nanotechnology. An electronic literature research was performed utilizing PubMed in August 2022. Scientific publications, which examine resveratrol using nanotechnology, are discussed. The studies clearly indicate that resveratrol-loaded nanoparticles exhibited a remarkable anti-cancer activity in various hormone-sensitive and hormone-insensitive prostate cancer cell lines including docetaxel-resistant prostate-cancer cells. The types of nanoparticles that were used varied and influenced the outcome. Additionally, the meaning of the surface functionality of the nanoparticles is emphasized. No reduction of the anti-proliferative activity of resveratrol was shown when used encapsulated. Additionally, synergistic effects of resveratrol and docetaxel were proven. Resveratrol-loaded nanoparticles, especially when combined, may represent the next generation of anticancer substances. However, further in vivo/clinical studies are necessary to confirm their clinical effectiveness.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白藜芦醇用作纳米治疗剂:一种有前途的额外治疗工具,用于治疗激素敏感、激素不敏感和耐药前列腺癌。
前列腺癌是男性最常见的癌症之一。尽管针对不同类型和阶段开发了不同的治疗药物,但疾病的进展或扩散是不可避免的。另一个问题是癌细胞对现有疗法的耐药性的发展。因此,迫切需要额外的药物。白藜芦醇是一种多酚类植物抗毒素,存在于许多植物和水果中,如红葡萄或蓝莓。白藜芦醇具有抗增殖、抗血管生成和抗癌作用,在包括前列腺癌在内的不同类型的癌症中已得到证实。迄今为止,由于溶解度差、生物利用度低和其他限制因素,未在临床上使用。为了克服这些限制,在过去的几年里,新型的纳米颗粒基配方被开发出来。本文综述了近年来有关白藜芦醇对前列腺癌细胞作用的研究进展,重点介绍了纳米技术的研究进展。利用PubMed于2022年8月进行了电子文献研究。讨论了利用纳米技术研究白藜芦醇的科学出版物。这些研究清楚地表明,白藜芦醇负载纳米颗粒在多种激素敏感和激素不敏感的前列腺癌细胞系中表现出显著的抗癌活性,包括多西他赛耐药的前列腺癌细胞。所使用的纳米颗粒类型各不相同,影响了结果。此外,强调了纳米颗粒表面功能的意义。白藜芦醇包封使用时,其抗增殖活性没有降低。此外,还证实了白藜芦醇和多西他赛的协同作用。白藜芦醇负载的纳米颗粒,特别是当结合时,可能代表下一代抗癌物质。然而,需要进一步的体内/临床研究来证实其临床有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
8.30%
发文量
0
期刊最新文献
A Mendelian randomisation approach to explore genetic factors associated with erectile dysfunction based on pooled genomic data. Administering antibiotic-loaded irrigation fluid as an alternative for prophylactic intravenous antibiotics in transurethral ureterolithotripsy (TUL): a randomized controlled trial. Decreased expression of LncRNA CRYM-AS1 promotes apoptosis through the Hippo-YAP1 signaling pathway leading to diabetic erectile dysfunction. Minimally invasive management of extraperitoneal bladder injury with extension to the trigone of the bladder with bilateral external ureteral catheterization: innovative approach instead of open surgical treatment. N4-acetyl-sulfamethoxazole stone in a patient on chronic trimethoprim/sulfamethoxazole therapy: a case report and literature review.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1